<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03194230</url>
  </required_header>
  <id_info>
    <org_study_id>P160908</org_study_id>
    <nct_id>NCT03194230</nct_id>
  </id_info>
  <brief_title>Interest of Cervical Dilators in Second Trimester Termination of Pregnancy</brief_title>
  <acronym>DILATOP</acronym>
  <official_title>Interest of Cervical Dilators in the Induction of Labor in Second Trimester Medical Termination of Pregnancy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INSERM U1153</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the use of cervical dilators for cervical
      ripening in case of second trimester medical termination of pregnancy (TOP) is effective to
      reduce duration of labor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Termination of pregnancy is a distressing and painful procedure for women. The use of
      cervical dilators could shorten the duration of labor but can generate more pain. The
      investigators will compare two procedures of induction of labor for second trimester
      termination of pregnancy: one with the use of vaginal prostaglandins (misoprostol) only and
      one with the exact same procedure preceded by cervical ripening with hygroscopic cervical
      dilators. Epidural analgesia will be effective previously to the placement of cervical
      dilators and the first tablet of misoprostol. Efficacy will be determined based on the
      proportion of women achieving vaginal delivery within 12 hours. The beginning of labor will
      be defined as the first placement of misoprostol tablets in both groups. In the group with
      dilators, the first tablets of misoprostol will be placed at the same time of the dilators.

      The investigators will also evaluate safety by collecting hemorrhage endometritis, cervical
      tear. The investigators will compare psychological impact of these procedures, measured by
      the impact of event scale and acceptability 1 to 4 months later.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2017</start_date>
  <completion_date type="Anticipated">February 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of women achieving vaginal delivery within 12 hours</measure>
    <time_frame>12 hours</time_frame>
    <description>The beginning of labor will be defined as the placement of the first tablets of misoprostol in both groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Induction-to-amniotomy interval</measure>
    <time_frame>12 hours</time_frame>
    <description>Time between the first placement of misoprostol tablets and artificial amniotomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction-to-delivery interval</measure>
    <time_frame>24 hours</time_frame>
    <description>Time between the first placement of misoprostol tablets and delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure in induction of labor</measure>
    <time_frame>24 hours</time_frame>
    <description>Proportion of women not achieving vaginal delivery within 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment at the beginning of the procedure</measure>
    <time_frame>Hour 0</time_frame>
    <description>Pain assessment with numerical scale at the placement of dilators and the first misoprostol tablets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment of the whole procedure of TOP</measure>
    <time_frame>48 hours</time_frame>
    <description>Pain assessment of the whole procedure by numerical scale at discharge of the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distress assessment at discharge after TOP</measure>
    <time_frame>4 months</time_frame>
    <description>Distress assessment at discharge after TOP measured by impact of event scale revised(IES-R)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of acceptability of the whole procedure of TOP</measure>
    <time_frame>4 months</time_frame>
    <description>Acceptability measured by the proportion of women who would opt for the same procedure after TOP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of complications.</measure>
    <time_frame>4 months</time_frame>
    <description>Hyperthermia&gt; 40 ° C, septicemia, endometritis defined by a fever associated with pelvic pain, positive bacteriological vaginal specimen and a biological infectious syndrome (leukocytosis greater than 15 000 / mm3 and C-Reactive Protein &gt; 10 IU / mL).
Cervical injury.
Complications of prolonged decubitus: bedsores, thrombo-embolic complications.
Uterine rupture.
Post-partum hemorrhage defined by estimated blood losses greater than 500 mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization.</measure>
    <time_frame>48 hours</time_frame>
    <description>Duration of hospitalization between admission and discharge and in delivery room.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of the procedure</measure>
    <time_frame>4 months</time_frame>
    <description>Assessment of the whole procedure costs of TOP, including potential complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Among nullipara, proportion of women achieving vaginal delivery within 12 hours</measure>
    <time_frame>12 hours</time_frame>
    <description>The beginning of labor will be defined as the placement of the first tablets of misoprostol in both groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Termination of Pregnancy (TOP)</condition>
  <arm_group>
    <arm_group_label>Without cervical dilator</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Induction of labour by vaginal placement of 2 tablets of misoprostol each 3 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>With cervical dilator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction of labour by cervical placement of hygroscopic dilators for 3 hours and vaginal placement of 2 tablets of misoprostol each 3 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>With cervical dilatator</intervention_name>
    <description>Induction of labour by cervical placement of hygroscopic dilators (Dilapan-S Hygroscopic cervical dilator )</description>
    <arm_group_label>With cervical dilator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Termination of pregnancy requested by the patient and accepted by the weekly
             multidisciplinary counselling of fetal medicine

          -  gestational age between 15 and 27 weeks and 6 days,

          -  single pregnancy,

          -  major patient,

          -  French-speaking woman,

          -  Patient with health insurance.

        Exclusion Criteria:

          -  Termination of pregnancy by surgical technique

          -  cicatricial uterus

          -  premature rupture of membranes

          -  chorioamnionitis

          -  multiple pregnancy

          -  placenta praevia

          -  myoma praevia

          -  uterine malformation

          -  unstable maternal pathology

          -  psychiatric pathology

          -  contraindication to mifepristone: severe asthma, adrenal insufficiency, porphyria,
             corticotherapy.

          -  contraindication to misoprostol: hypersensitivity to prostaglandins.

          -  contraindication to epidural analgesia: hemostasis disorder, spinal or medullary
             anomaly.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vassilis Tsatsaris, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivia Anselem, MD</last_name>
    <phone>158 41 37 63</phone>
    <phone_ext>+33</phone_ext>
    <email>olivia.anselem@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurence Lecomte, PhD</last_name>
    <phone>1 71 19 64 94</phone>
    <phone_ext>+33</phone_ext>
    <email>laurence.lecomte@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maternité Port Royal</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>olivia Anselem, MD</last_name>
      <phone>1 58 41 37 63</phone>
      <phone_ext>+33</phone_ext>
      <email>olivia.anselem@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Vassilis Tsatsaris, MD, PhD</last_name>
      <phone>1 58 41 38 71</phone>
      <phone_ext>+33</phone_ext>
      <email>vassilis.tsatsaris@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Vincienne M, Anselem O, Cordier AG, Le Ray C, Tsatsaris V, Benachi A, Goffinet F. Comparison of the Induction-to-Delivery Interval in Terminations of Pregnancy with or without Dilapan-S®. Fetal Diagn Ther. 2018;43(1):61-67. doi: 10.1159/000458410. Epub 2017 Mar 29.</citation>
    <PMID>28351055</PMID>
  </reference>
  <reference>
    <citation>Jain JK, Mishell DR Jr. A comparison of misoprostol with and without laminaria tents for induction of second-trimester abortion. Am J Obstet Gynecol. 1996 Jul;175(1):173-7.</citation>
    <PMID>8694046</PMID>
  </reference>
  <reference>
    <citation>Mazouni C, Vejux N, Menard JP, Bruno A, Boubli L, d'Ercole C, Bretelle F. Cervical preparation with laminaria tents improves induction-to-delivery interval in second- and third-trimester medical termination of pregnancy. Contraception. 2009 Jul;80(1):101-4. doi: 10.1016/j.contraception.2009.01.013. Epub 2009 Mar 4.</citation>
    <PMID>19501224</PMID>
  </reference>
  <reference>
    <citation>Pluchon M, Winer N. [Misoprostol in case of termination of pregnancy in the second and third trimesters. Trials]. J Gynecol Obstet Biol Reprod (Paris). 2014 Feb;43(2):162-8. doi: 10.1016/j.jgyn.2013.11.009. Epub 2014 Jan 16. Review. French.</citation>
    <PMID>24440001</PMID>
  </reference>
  <reference>
    <citation>Gitz L, Morel O, Thiebaugeorges O, Sibiude J, Desfeux P, Barranger E. [Termination of pregnancy and intra-uterine fetal death after 14 weeks of pregnancy: Which protocol for induction of labour in 2010?]. J Gynecol Obstet Biol Reprod (Paris). 2011 Feb;40(1):1-9. doi: 10.1016/j.jgyn.2010.11.007. Epub 2010 Dec 23. Review. French.</citation>
    <PMID>21185133</PMID>
  </reference>
  <reference>
    <citation>Thong KJ, Baird DT. A study of gemeprost alone, dilapan or mifepristone in combination with gemeprost for the termination of second trimester pregnancy. Contraception. 1992 Jul;46(1):11-7.</citation>
    <PMID>1424619</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2017</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical dilators</keyword>
  <keyword>induction of labor</keyword>
  <keyword>cervical ripening</keyword>
  <keyword>medical termination of pregnancy</keyword>
  <keyword>second-trimester of pregnancy.</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

